Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

Sign up to our free daily newsletter for daily roundups of the biggest headlines and breaking news from SurreyLive ...